We reviewed trials that tested the efficacy of antihypertensive drugs in reducing arterial stiffness and wave reflections as assessed by pulse wave velocity and augmentation index, respectively. Regardless of cross-over or parallel-group comparison design, placebo-controlled trials demonstrated that antihypertensive drugs were effective in reducing pulse wave velocity. In actively-controlled parallel-group comparison studies, this effect on arterial stiffness was more evident for angiotensin-converting enzyme inhibitors or angiotensin receptor blockers than other classes of antihypertensive drugs, particularly when brachial-ankle pulse wave velocity was measured. Regardless of cross-over or parallel-group comparison or placebo-or activelycontrolled design, the reviewed trials showed that β-blockers were inferior to all the other classes of antihypertensive drugs in reducing augmentation index. However, these studies had a small sample size and a short follow-up time and did not link the changes in measurements of arterial function with cardiovascular events. Whether the superiority or inferiority is clinically relevant for cardiovascular protection and prevention remains to be investigated.
Introduction
In the past 2 decades, noninvasive measurements of arterial function are increasingly used as an intermediate measure of cardiovascular disease risk in therapeutic trials, such as antihypertensive therapy. Among various parameters of arterial function, pulse wave velocity and augmentation index measure arterial stiffness and wave reflections, respectively. Both angiotensin receptor blockers (ARBs; n = 3) [5, 30, 31] , β-blockers (n = 7) [1] [2] [3] [4] [32] [33] [34] , calcium channel blockers (CCBs; n = 3) [2, 3, 33] , and diuretics (n = 2) [2, 3] , 2 comparisons of ARBs with β-blockers [35, 36] , 6 comparisons between 2 different β-blockers (n = 1) [10] or of β-blockers with CCBs (n = 3) [2, 3, 33] and diuretics (n = 2) [2, 3] , 3 comparisons of CCBs with diuretics [2, 3, 37] , and 2 comparisons of combination therapy with each of their component drugs [30, 38] . In these short-term cross-over studies, antihypertensive drugs had similar arterial effects, except that β-blockers were inferior to the other classes of antihypertensive drugs in reducing augmentation index in 11 of 14 comparisons with ACE inhibitors, ARBs, CCBs, or diuretics.
Of the parallel group trials, 20, 4, and 7 studied pulse wave velocity [13, 16, 26, 39-43, 46, 47, 49, 52-56, 58-60, 62] , augmentation index alone [23, 48, 57, 63] , and both [44, 45, 50, 51, 61, 64, 65] , respectively ( table 4 ). These trials included 20 comparisons of ACE inhibitors with ARBs (n = 6) [16, [39] [40] [41] [42] [43] , β-blockers (n = 2) [13, 44] , CCBs (n = 8) [13, 39, 40, [43] [44] [45] [46] , and diuretics (n = 4) [44, 47-49] , 13 comparisons of ARBs with β-blockers (n = 2) [50, 51] , [4] 2002 EH 30 lisinopril not measured AIx NS Morgan [5] 2004 EH 32 ACEIs not measured AIx NS Hirata [6] 2005 CAD 30 ramipril cfPWV ramipril better AIx and AIx@HR75 ramipril better Turner [7] 2006 intracranial aneurysms [3] 2001 EH 20 atenolol AUC cfPWV atenolol better AUC AIx NS Deary [4] 2002 EH 30 bisoprolol not measured AIx bisoprolol better Morgan [5] 2004 EH 32 β-blockers not measured AIx NS Hirata [6] 2005 CAD 30 atenolol cfPWV atenolol better AIx atenolol worse; AIx@HR75 NS Dhakam [12] 2008 [5] 2004 EH 32 diuretics not measured AIx NS Davies [13] 2005 EH/DM 10 spironolactone crPWV spironolactone better not measured ACEIs = ACE inhibitors; AIx = augmentation index; AIx@HR75 = AIx corrected for heart rate of 75 beats/min; aPWV = aortic pulse wave velocity; AUC = area under the curve; CAD = coronary artery disease; cfPWV = carotid-femoral pulse wave velocity; crPWV = carotid-radial pulse wave velocity; DM = diabetes mellitus; EH = essential hypertension; NS = not significantly different.
CCBs (n = 10) [39, 40, 43, [52] [53] [54] [55] [56] [57] [58] , or a diuretic (n = 1) [23] , 5 comparisons of β-blockers with CCBs (n = 4) [13, 26, 44, 59] or a diuretic (n = 1) [44] , 7 comparisons between 2 different CCBs (n = 1) [40] or of CCBs with diuretics (n = 6) [44, [60] [61] [62] [63] [64] , and 2 comparisons of combination therapy with one [65] or two of their component drugs [41] . In these studies, ACE inhibitors or ARBs tended to be more efficacious than other classes of antihypertensive drugs in reducing arterial stiffness, especially when brachial-ankle pulse wave velocity was measured in 11 trials [16, 40, 41, 43, 46, 52-54, 56, 58, 62] . The results were not consistent for other comparisons of pulse wave velocity or for studies on augmentation index, except that β-blockers were inferior to the other classes of antihypertensive drugs in reducing augmentation index in all 5 comparisons with an ACE inhibitor (n = 1) [44] , ARBs (n = 2) [50, 51] , a CCB (n = 1) [44] , or a diuretic (n = 1) [44] . [15] 2001 open EH 111 perindopril not measured AIx NS Ichihara [16] 2005 -hemodialysis patients 42 trandolapril baPWV trandolapril better not measured Yu [17] 2006 DB hemodialysis patients 46 ramipril cfPWV NS AIx NS Tsang [18] 2006 DB IDD 21 quinapril not measured AIx NS Ahimastos [19] 
Conclusions and Perspectives
Our narrative review was informative on three clinically relevant questions. First, antihypertensive drugs are effective in reducing arterial stiffness. However, this effect does not at all infer any benefit above and beyond blood pressure lowering. In contrast, because pulse wave velocity is dependent on systolic blood pressure, the therapeutic effect of antihypertensive drugs on arterial stiffness, to some extent if not entirely, can be attributable to their blood pressure lowering efficacy. Second, though all antihypertensive drugs reduce arterial stiffness, ACE inhibitors or ARBs might be more efficacious than other classes of antihypertensive drugs. This effect is more evident when brachial-ankle pulse wave velocity is measured. The mechanism remains to be elucidated. Third, as also evidenced by a recent meta-analysis of randomized controlled trials that compared β-blockers with the other classes of antihypertensive drugs [66] , because of the intrinsic heart rate slowing effect, β-blockers are inferior to all the other classes of antihypertensive drugs in reducing augmentation index. However, whether this inferiority is clinically relevant for cardiovascular protection and prevention remains to be investigated.
In spite of a large number of trials that studied the efficacy of antihypertensive drugs in reducing pulse wave velocity and augmentation index, these studies had a small sample size and a short follow-up time and did not link the changes in measurements of arterial function with cardiovascular events. It is therefore imperative to combine the research force in the field of arterial functions to run adequately powered outcome trials to investigate whether arterial stiffness and wave reflections are clinically useful in monitoring the effect of antihypertensive treatment and other cardiovascular therapeutic approaches. [41] 2005 -EH 21 perindopril + valsartan vs. perindopril vs. valsartan baPWV combination better not measured ACEIs = ACE inhibitors; AIx = augmentation index; AIx@HR75 = AIx corrected for heart rate of 75 beats/min; aPWV = aortic pulse wave velocity; baPWV = brachial-ankle pulse wave velocity; cfPWV = carotid-femoral pulse wave velocity; CKD = chronic kidney disease; DB = double-blinded; DM = diabetes mellitus; EH = essential hypertension; ESRD = end-stage renal dysfunction; NS = not significantly different; SB = single-blinded. 
